Lorlatinib

Today is World Lung Cancer Day.

Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.

CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.

Lorlatinib appeared safe and showed potential efficacy among a cohort of patients with relapsed or refractory, ALK-driven, high-risk neuroblastoma, results of a phase 1 trial showed.

CHICAGO — Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.

The FDA expanded the approval of lorlatinib to include the first-line treatment of adults with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

The FDA granted priority review to lorlatinib for first-line treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, according to the agent’s manufacturer.

Lorlatinib appeared to be an effective first-line therapy compared with crizotinib among patients with advanced ALK-positive non-small cell lung cancer, according to phase 3 study results published in The New England Journal of Medicine.

Lorlatinib appeared superior to crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer, according to an interim analysis of the randomized phase 3 CROWN study presented at ESMO Virtual Congress 2020.

Lorlatinib appeared to be an effective treatment for non-small cell lung cancer with ALK resistance mutations, regardless of EML4-ALK variants, according to results of a study presented at the virtual American Association for Cancer Research Annual Meeting.